Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
721 Clinic Dr
Ste A
Tyler, TX 75701Phone+1 903-592-6152Fax+1 903-526-0629
Education & Training
Baylor College of MedicineFellowship, Hematology, 1985 - 1987- Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
- Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- TR(ACE) Assay Clinical Specimen Study Start of enrollment: 2016 Sep 01
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Publications & Presentations
PubMed
- 60 citationsPhase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.Carryn M. Anderson, Christopher M. Lee, Deborah P. Saunders, Amarinthia Curtis, Neal Dunlap
Journal of Clinical Oncology. 2019-10-16 - 4 citationsA multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).Sharmeen Mahmood, Daneng Li, Arielle Lee, Julie Rowe, Muhammed Beg
Future Oncology. 2022-12-01 - 5 citationsTwo-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurre...Carryn M Anderson, Christopher M Lee, Deborah Saunders, Amarinthia E Curtis, Neal E Dunlap
International Journal of Radiation Oncology, Biology, Physics. 2022-11-01
Press Mentions
- Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
